COMPANIES · AI APPLICATIONS

Tempus AI

Tempus AI is a publicly traded precision-medicine company that combines clinical and molecular data with AI models to help doctors choose cancer and other disease treatments and to support pharmaceutical drug development.

ApplicationAI applications
What it does

Tempus AI is a publicly traded precision-medicine company that combines clinical and molecular data with AI models to help doctors choose cancer and other disease treatments and to support pharmaceutical drug development.

Why it matters

Tempus AI is one of the few pure-play AI-driven healthcare companies to reach the public markets, and its partnerships with drugmakers and technology investors show how AI is being layered onto existing genomic-testing and diagnostics businesses.

How it makes money

Tempus AI earns revenue from genomic and diagnostic testing services sold to healthcare providers and from data-licensing and drug-development collaborations with pharmaceutical companies.

Geography

United States (Chicago, Illinois)

AI stack position

AI applications. Companies putting AI to work in real products across healthcare, finance, coding, legal, defense and more. This is where AI actually reaches everyday users and businesses.

Same-layer peers

Same-layer peers share an editorial stack classification; that alone does not establish direct competition.

Connections (2)

Every connection below is tied to a readable source, date, classification and statement of its limits. A company source establishes what that company stated; it does not necessarily provide independent confirmation.

Current relationships (2)

Google (Alphabet subsidiary) invested in Tempus's Series G-2 round Tempus AI
Invested inCurrent
Tempus announced a $200 million Series G-2 financing round in 2024 that included investment from Google, bringing Tempus's valuation above $8 billion at the time.

Source: 2024-06-19 · reviewed 2026-09-20

Evidence: Secondary reporting (unconfirmed by primary parties) · Completed pre-IPO funding round

Limits: Confirms Google's participation in a funding round; does not disclose the investment amount attributable to Google specifically or Google's resulting ownership percentage after Tempus's 2024 IPO.

Google Invested in This Hot New Artificial Intelligence (AI) Stock. Should You? ↗
Tempus AI formed a healthcare AI joint venture with SoftBank Group
Partners withCurrent
SoftBank Group and Tempus AI announced a partnership to launch an AI-driven healthcare venture together.

Source: Source undated · reviewed 2026-09-20

Evidence: Primary-source statement · Active joint venture

Limits: Confirms a joint venture was announced; does not disclose the venture's current operating status, financial structure, or ownership split.

SoftBank launches healthcare venture with Tempus AI ↗
Evidence for this profile

Tempus AI ↗
Reviewed

Explore it interactively

Open this profile in the database See it on the relationship map

Inclusion in this database is not an endorsement of a company or its securities. Nothing here is a recommendation to buy or sell anything, and none of it is individualized investment advice. See the disclosures. Data: AI Map v3.22, released .